Abstract:Research demonstrates that the neural mechanisms underlying synaptic plasticity and learning and memory involve mobilization of AMPA-type neurotransmitter receptors at glutamatergic synaptic contacts, and that these mechanisms are targeted during neurodegenerative disease. Strengthening neural transmission occurs with insertion of α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptors (AMPARs) into synapses while weakening results from receptor withdrawal. A key player in the trafficking of AMPARs during plasticity and learning is the brain-derived neurotrophic factor (BDNF) signaling system. BDNF is a neurotrophic factor that supports neuronal growth and is required for learning and memory. Significantly, a primary feature of many neurodegenerative diseases is a reduction in BDNF protein as well as disrupted neuronal surface expression of synaptic AMPARs. The resulting weakening of synaptic contacts leads to synapse loss and neuronal degeneration that underlies the cognitive impairment and dementia observed in patients with progressive neurodegenerative disease such as Alzheimer's. In the face of these data, one therapeutic approach is to increase BDNF bioavailability in brain. While this has been met with significant challenges, the results of the research have been promising. In spite of this, there are currently no clinical trials to test many of these findings on patients. Here, research showing that BDNF drives AMPARs to synapses, AMPAR trafficking is essential for synaptic plasticity and learning, and that neurodegenerative disease results in a significant decline in BDNF will be reviewed. The aim is to draw attention to the need for increasing patient-directed clinical studies to test the possible benefits of increasing levels of neurotrophins, specifically BDNF, to treat brain disorders. Much is known about the cellular mechanisms that underlie learning and memory in brain. It can be concluded that signaling by neurotrophins like BDNF and AMPA-type glutamate receptor synaptic trafficking are fundamental to these processes. Data from animal models and patients reveal that these mechanisms are adversely targeted during neurodegenerative disease and results in memory loss and cognitive decline. A brief summary of our understanding of these mechanisms indicates that it is time to apply this knowledge base directly to development of therapeutic treatments that enhance neurotrophins for brain disorders in patient populations.

Targeting synapse function and loss for treatment of neurodegenerative diseases

Targeting the Synapse in Alzheimer’s Disease

BDNF-based synaptic repair as a disease-modifying strategy for neurodegenerative diseases

The synapse as a treatment avenue for Alzheimer’s Disease

Synaptic Vulnerability in Neurodegenerative Disease

Synaptic Secretion and Beyond: Targeting Synapse and Neurotransmitters to Treat Neurodegenerative Diseases

Novel Molecular Targets and Mechanisms for Neuroprotective Modulation in Neurodegenerative Disorders

The clinical promise of biomarkers of synapse damage or loss in Alzheimer’s disease

Targeting Microglia-Synapse Interactions in Alzheimer's Disease

A review of proposed mechanisms for neurodegenerative disease

Regulation of AMPAR trafficking in synaptic plasticity by BDNF and the impact of neurodegenerative disease

Synaptic dysfunction in neurodegenerative and neurodevelopmental diseases: an overview of induced pluripotent stem-cell-based disease models

Treating Alzheimer's Disease: Focusing on Neurodegenerative Consequences

Synaptopathy: presynaptic convergence in frontotemporal dementia and amyotrophic lateral sclerosis

Targeting brain-derived neurotrophic factor in the treatment of neurodegenerative diseases: A review

Target- and mechanism-based therapeutics for neurodegenerative diseases: strength in numbers

Targeting BDNF Signaling by Natural Products: Novel Synaptic Repair Therapeutics for Neurodegeneration and Behavior Disorders.

Dysfunction of Wnt signaling and synaptic disassembly in neurodegenerative diseases

Cognitive synaptopathy: synaptic and dendritic spine dysfunction in age-related cognitive disorders

Synaptic Function As a Preclinical and Experimental Medicine Readout for Disease-Modifying Therapy in Alzheimer's Disease